(CercleFinance.com) – Novartis and Molecular Partners report positive foreground data from the Phase 2 study for ensovibep (MP0420), a DARPin antiviral therapy for COVID-19.
Novartis will exercise its option, paying 150 million Swiss francs to ensovibep under license from Molecular Partners, accelerating the scale-up of manufacturing and plans to seek expedited regulatory clearances globally.
The first results of the randomized EMPATHY Part A study in acute COVID-19 ambulatory patients comparing single intravenous doses of ensovibep, a DARPin antiviral therapeutic candidate against placebo, met the primary endpoint of viral load reduction in eight days.
The secondary endpoint of hospitalization and / or emergency room visits related to COVID-19 or death showed an overall reduction of 78% in the risk of ensovibep events compared to placebo.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
